Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Co-promotion

Thumbnail
October 28, 2020

Another complement factor enters the deal-making frame

Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.

Thumbnail
August 07, 2020

Biogen pays $560m for an unproven Parkinson’s mechanism

All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.

Article image
Vantage logo
April 15, 2020

Another endorsement for PI3K delta, this time in oncology

Article image
Vantage logo
April 09, 2020

Circassia’s fall from grace might be complete

Article image
Vantage logo
January 13, 2020

Morphosys gets a major tafasitamab endorsement

Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.

Article image
Vantage logo
November 01, 2019

Breaking down Beigene’s latest deal with the west

A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.

Article image
Vantage logo
October 31, 2019

One step forward, two steps back for prescription apps

Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.

Article image
Vantage logo
October 28, 2019

Another robot deal for J&J shows up lack of Verb results

Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.

Article image
Vantage logo
July 15, 2019

Through Gilead, Galapagos secures an independent future

For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come. 

Article image
Vantage logo
October 23, 2018

Astrazeneca asset swap kickstarts Innate's independence

Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.

Article image
Vantage logo
August 23, 2018

Promotion deal is huge boost for Exact – but Pfizer must deliver

Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.